For severe radiation pneumonitis/pneumonia (grade 3 or higher), neither PD-1-targeting treatments (RR = 0.93, 95% CI 0.10-8.31) nor PD-L1-targeting treatments (RR = 1.15, 95% CI 0.77-1.70) demonstrated a statistically significant impact on incidence (Table 3). This evidence concerns the gene CD274 and susceptibility to pneumonia measurement.